ArticleFrontiers in immunology2026
Case Report: Efficacy of efgartigimod for autonomic dysfunction in patients with autoimmune glial fibrillary acidic protein astrocytopathy: a case series of 3 patients.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Efgartigimod can rapidly reduce serum IgG antibody levels and decrease antibody-mediated neuroinflammation and damage. It is primarily used to treat autoimmune diseases. Glial fibrillary acidic protein astrocytopathy (GFAP-A) is a disease of the central nervous system characterized by GFAP antibodies. It has a high incidence of autonomic dysfunction in patients and there is currently no effective treatment plan. It is not known whether efgartigimod can improve autonomic dysfunction in GFAP-A. Case presentation: All three patients with GFAP-A presented with autonomic dysfunction, which manifested as urinary and defecatory disorders. Marked remission of corticosteroid-refractory autonomic dysfunction was observed following combined treatment with efgartigimod and corticosteroids. All three patients presented with autonomic dysfunction. Patient 1 experienced marked improvement in autonomic function after the addition of efgartigimod, despite showing no significant improvement after high-dose pulse steroid therapy. Patient 2 showed no significant improvement after treatment with low-dose steroids, but achieved complete recovery of autonomic dysfunction after efgartigimod treatment. Patient 3 initially received low-dose steroids, with no significant improvement in autonomic dysfunction. After switching to a high dose of steroids combined with efgartigimod, the patient's autonomic dysfunction gradually improved. Conclusion: We observed that after combined treatment with efgartigimod and corticosteroids, the corticosteroid-refractory autonomic dysfunction in GFAP-A patients was significantly alleviated, providing a new clinical treatment option. However, this article is based on a small sample size and requires further validation through larger-scale studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.